No photo of Edward L. Schwartz

View Scopus Profile

Edward L. Schwartz, Ph.D.

  • 4290 Citations
  • 31 h-Index
1977 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Edward L. Schwartz is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis

Schwartz, E. L.

National Cancer Institute

6/1/19 → 5/31/20

Project: Research project

    • Vulnerability of SCLC based on bi-allelic genetic inactivation of RB1 and TP53

    Schwartz, E. L. & Zhao, H.

    National Cancer Institute

    4/12/19 → 3/31/20

    Project: Research project

    • Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis

    Schwartz, E. L.

    National Cancer Institute

    7/9/12 → 5/31/13

    Project: Research project

    • Anti-angiogenic actions of taxotere

    Schwartz, E. L.

    National Cancer Institute

    9/29/03 → 8/31/04

    Project: Research project

    • Mechanisms of thymidine phosphorylase angiogenesis

    Schwartz, E. L.

    National Cancer Institute

    6/1/01 → 5/31/02

    Project: Research project

    • Publications

    • 4290 Citations
    • 31 h-Index
    • 83 Article
    • 5 Review article
    • 2 Letter

    Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer

    Zhao, H., Iqbal, N. J., Sukrithan, V., Nicholas, C., Xue, Y., Yu, C., Locker, J., Zou, J., Schwartz, E. L. & Zhu, L., Jun 1 2020, In : Cancer research. 80, 11, p. 2355-2367 13 p.

    Research output: Contribution to journal › Article

    • Lysosome membrane permeabilization and disruption of the molecular target of rapamycin (mTOR)-lysosome interaction are associated with the inhibition of lung cancer cell proliferation by a chloroquinoline analog

    Sironi, J. J., Aranda Jaque, E. J., Nordstrøm, L. U. & Schwartz, E. L., Jan 2019, In : Molecular Pharmacology. 95, 1, p. 127-138 12 p.

    Research output: Contribution to journal › Article

    • 4 Scopus citations

    Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells

    Nordstrøm, L. U., Sironi, J., Aranda, E., Maisonet, J., Perez-Soler, R., Wu, P. & Schwartz, E. L., Feb 12 2015, In : ACS Medicinal Chemistry Letters. 6, 2, p. 134-139 6 p.

    Research output: Contribution to journal › Article

    • 14 Scopus citations

    RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors

    Cheng, H., Zou, Y., Ross, J. S., Wang, K., Liu, X., Halmos, B., Ali, S. M., Liu, H., Verma, A., Montagna, C., Chachoua, A., Goel, S., Schwartz, E. L., Zhu, C., Shan, J., Yu, Y., Gritsman, K., Yelensky, R., Lipson, D., Otto, G. & 5 others, Hawryluk, M., Stephens, P. J., Miller, V. A., Piperdi, B. & Perez-Soler, R., Dec 2015, In : Cancer discovery. 5, 12, p. 1262-1270 9 p.

    Research output: Contribution to journal › Article

    • 50 Scopus citations

    Stilbene 5c, a microtubule poison with vascular disrupting properties that induces multiple modes of growth arrest and cell death

    Alotaibi, M. R., Asnake, B., Di, X., Beckman, M. J., Durrant, D., Simoni, D., Baruchello, R., Lee, R. M., Schwartz, E. L. & Gewirtz, D. A., Nov 12 2013, In : Biochemical Pharmacology. 86, 12, p. 1688-1698 11 p.

    Research output: Contribution to journal › Article

    • 6 Scopus citations